Global Drugs For Erectile Dysfunction Market Forecast to Reach $4.42 Billion by 2029, Driven by CAGR
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Forecasted Growth Rate and Market Size of the Drugs For Erectile Dysfunction Market?
The market size for erectile dysfunction medications has seen a slight decrease in the past few years. Its size is projected to increase from “$4.16 billion in 2024 to $4.15 billion in 2025, with a compound annual growth rate (CAGR) of -0.2%. The growth during the past period can be credited to the debut of PDE5 inhibitors, efforts in pharma marketing and advertising, evolving societal perpsectives, and an increase in lifestyle-related ED incidents, as well as the presence of generic drugs.
In the coming years, the market size for erectile dysfunction drugs is projected to experience slight growth, expanding to “$4.42 billion in 2029 at a compound annual growth rate (CAGR) of 1.6%. Various factors contributing to this predicted increase in the forecast period include the integration of mental health focus, changes in consumer preferences, market growth in developing economies, exploration of regenerative medicine, and innovations in biopharmaceuticals. Key trends forecasted for this period involve the development of unique therapies, heightened awareness and education, alterations in lifestyle and health consciousness, telemedicine and internet-based consultations, and breakthroughs in delivery systems.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2443&type=smp
Which Factor Is Shaping The Future Of The Drugs For Erectile Dysfunction Market?
The sharp upsurge in chronic diseases serves as the driving force for the erectile dysfunction drugs market. Principal causes of erectile dysfunction are chronic ailments that arise from a sedentary lifestyle such as heart diseases, diabetes, obesity, and hypertension. For instance, the World Health Organization (WHO), a United Nations agency based in Switzerland that advocates global health and safety, stated in September 2023, that 41 million individuals die from chronic diseases annually. This amounts to 74% of total global deaths. Hence, the sharp rise in chronic diseases propels the erectile dysfunction market forward.
The drugs for erectile dysfunction market covered in this report is segmented –
1) By Drugs: Sildenafil Citrate, Mirodenafil , Vardenafil
2) By Mode Of Administration: Oral, Topical, Injections
3) By End Users: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Sildenafil Citrate: Brand Names (Viagra), Generic Forms, Dosage Forms (Tablets, Chewables)
2) By Mirodenafil: Brand Names (Mvix), Dosage Forms, Combination Products
3) By Vardenafil: Brand Names (Levitra, Staxyn), Dosage Forms, Administration Routes (Oral, Dissolvable)
What Notable Trends Are Shaping The Direction Of The Drugs For Erectile Dysfunction Market?
Numerous companies in the erectile dysfunction drugs market are adopting innovative drug delivery methods such as pellets and creams. These methods offer enhanced effectiveness and safety in treating erectile dysfunction, thereby broadening the scope of the erectile dysfunction drug market. For instance, Lupin, a pharmaceutical firm based in India, launched Sildenafil for oral suspension, at a dosage of 10 mg/mL, in September 2022. This launch was approved by the United States Food and Drug Administration (FDA) and the drug is used to treat erectile dysfunction with unique dosages.
Which Companies Hold The Largest Market Share In The Drugs For Erectile Dysfunction Sector?
Major companies operating in the drugs for erectile dysfunction market include Pfizer Inc., Eli Lilly and Company, Bayer AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Futura Medical plc, Zydus Cadila, Lupin Limited, Cipla Limited, Dong-A Pharmaceutical Co., Ltd., Aurobindo Pharma Ltd., Alembic Pharmaceuticals Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., AvKARE Inc., Endo Pharmaceuticals Inc., Teva Pharmaceutical USA, Aurobindo Pharma USA, Hims & Hers Health Inc., Antares Pharma Inc., Acrux Limited, Mankind Pharma Ltd., Futura Medical plc, Adamis Pharmaceuticals Corporation
How Does Regional Performance Compare Across The Drugs For Erectile Dysfunction Industry?
North America was the largest region in the drugs for erectile dysfunction market in 2024. Middle East is expected to be the fastest-growing region in the global drugs for erectile dysfunction market during the forecast period. The regions covered in the drugs for erectile dysfunction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=2443&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
